This retrospective study found no benefit of a disease management program compared with usual care on utilization of secondary prevention pharmacotherapies in postmyocardial infarction patients.
Vicky Chan, PharmD
Advertisement
Articles by Vicky Chan, PharmD
Advertisement
Latest Updated Articles
- Pharmacotherapy After Myocardial Infarction: Disease Management Versus Usual Care
Published: June 7th 2008 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5
